Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Erie
    4. ›
  4. 14203
    5. ›
  5. HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE, INC.

HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE, INC.

Company Details

Name: HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE, INC.
Jurisdiction: New York
Legal type: DOMESTIC NOT-FOR-PROFIT CORPORATION
Status: Active
Date of registration: 02 Nov 1956 (69 years ago)
Entity Number: 98132
ZIP code: 14203
County: Erie
Place of Formation: New York
Address: 73 HIGH STREET, BUFFALO, NY, United States, 14203

DOS Process Agent

Name Role Address
THE CORPORATION DOS Process Agent 73 HIGH STREET, BUFFALO, NY, United States, 14203

Agent

Name Role Address
THE MEDICAL FOUNDATION OF BUFFALO, INC. Agent 73 HIGH ST., BUFFALO, NY, 14203

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:
HVQYC8JZB9A6
CAGE Code:
0HSG9
UEI Expiration Date:
2025-01-08

Business Information

URL:
http://www.hwi.buffalo.edu
Activation Date:
2024-01-11
Initial Registration Date:
2001-09-06

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
0HSG9
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2024-03-10
CAGE Expiration:
2029-01-11
SAM Expiration:
2025-01-08

Contact Information

POC:
ANNE KENT
Phone:
+1 716-898-8589
Fax:
+1 716-898-8660

Form 5500 Series

Employer Identification Number (EIN):
160807558
Plan Year:
2023
Number Of Participants:
77
Sponsors Telephone Number:
7168988600
File:
View File
Plan Year:
2022
Number Of Participants:
74
Sponsors Telephone Number:
7168988600
File:
View File
Plan Year:
2021
Number Of Participants:
73
Sponsors Telephone Number:
7168988600
File:
View File
Plan Year:
2020
Number Of Participants:
70
Sponsors Telephone Number:
7168988600
File:
View File
Plan Year:
2019
Number Of Participants:
69
Sponsors Telephone Number:
7168988600
File:
View File

History

Start date End date Type Value
1994-09-07 2002-05-29 Address 73 HIGH STREET, BUFFALO, NY, 14203, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
20090515052 2009-05-15 ASSUMED NAME CORP INITIAL FILING 2009-05-15
020529000736 2002-05-29 CERTIFICATE OF AMENDMENT 2002-05-29
940907000298 1994-09-07 CERTIFICATE OF AMENDMENT 1994-09-07
A97831-3 1973-09-05 CERTIFICATE OF AMENDMENT 1973-09-05
38590 1956-11-02 CERTIFICATE OF INCORPORATION 1956-11-02

USAspending Awards / Contracts

Procurement Instrument Identifier:
HDTRA110C0057
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DCA
Awarding Agency Name:
Department of Defense
Performance Start Date:
2010-08-11
Description:
RESEARCH AND DEVELOPMENT ON: PREVENTING LONG-TERM BRAIN AND LUNG DAMAGE CAUSED BY BATTLEFIELD TRAUMA
Naics Code:
541711: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
Product Or Service Code:
AD92: OTHER DEFENSE (APPLIED/EXPLORATORY)
Procurement Instrument Identifier:
HDTRA109C0017
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DCA
Awarding Agency Name:
Department of Defense
Performance Start Date:
2009-07-30
Description:
PERIOD 2
Naics Code:
541711: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
Product Or Service Code:
AN12: BIOMEDICAL (APPLIED/EXPLORATORY)
Procurement Instrument Identifier:
V528D95009
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
PO
Awarding Agency Name:
Department of Veterans Affairs
Performance Start Date:
2008-10-01
Description:
SMALL PURCHASE DATA
Product Or Service Code:
AF11: EDUCATION (BASIC)

USAspending Awards / Financial Assistance

Date:
2024-08-16
Link:
View on USAspending
Awarding Agency Name:
Department of Energy
Transaction Description:
UNDERSTANDING THE MECHANISM AND HEALTH CONSEQUENCES OF LOW-DOSE RADIATION AT A MOLECULAR LEVEL
Obligated Amount:
499564.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2024-08-13
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
N-GLYCOSYLATION AS A REGULATOR OF GRP94 FUNCTION AND ACTIVITY - PROJECT SUMMARY MOST NEWLY SYNTHESIZED PROTEINS DESTINED FOR THE CELL SURFACE OR SECRETION MUST TRANSIT THROUGH THE ENDOPLASMIC RETICULUM (ER) FOR FOLDING AND POST-TRANSLATIONAL PROCESSING. GRP94, THE ER RESIDENT MEMBER OF THE HSP90 FAMILY OF CHAPERONES, IS REQUIRED FOR THE MATURATION OF VARIOUS MEMBRANE AND SECRETED PROTEINS. GRP94'S CONTROL OVER THE FATE OF THESE DIVERSE CLIENTS MAKES IT AN EMERGING THERAPEUTIC TARGET FOR A NUMBER OF CHRONIC DISEASES INCLUDING TYPE 2 DIABETES, FAMILIAL HYPERCHOLESTEROLEMIA, AND SEPSIS, AS WELL AS CANCERS SUCH AS HER2-POSITIVE BREAST CANCER AND MULTIPLE MYELOMA. AN UNANSWERED QUESTION IS HOW GRP94 ADAPTS TO DIFFERENT NEEDS WITHIN A DYNAMIC ER FOLDING ENVIRONMENT TO ENSURE EFFICIENT CLIENT CAPTURE AND FOLDING. DESPITE BEING THE MOST ABUNDANT PROTEIN IN THE ER, GRP94 IS EVEN FURTHER UPREGULATED UNDER CONDITIONS OF CELL STRESS OR DISEASE. THE INCREASED OVEREXPRESSION OF GRP94 CORRELATES WITH ITS HYPERGLYCOSYLATION, THE UTILIZATION OF THE FIVE MINOR GLYCOSYLATION SITES THAT ARE SPARINGLY OCCUPIED IN NONSTRESSED CELLS AND TISSUES. RECENT STUDIES HAVE SHOWN THAT HYPERGLYCOSYLATION IMPARTS NEW FUNCTIONS TO GRP94 THAT ARE ESSENTIAL FOR THE SUCCESSFUL RESPONSE TO STRESS OR MAINTENANCE OF THE PATHOLOGICAL STATE. OUR CENTRAL HYPOTHESIS IS THAT DIFFERENTIAL GLYCOSYLATION SERVES AS A TUNING MECHANISM THAT ALTERS THE FUNCTIONAL STATUS OF GRP94. A SYSTEMATIC ANALYSIS OF THE EFFECTS OF GLYCOSYLATION ON GRP94 HAS BEEN HAMPERED BY THE DIFFICULTY IN PRODUCING SITE-SPECIFIC, HOMOGENEOUS GLYCOPROTEINS THAT WOULD ALLOW FOR THE CLEAR INTERPRETATION OF FUNCTIONAL AND BIOCHEMICAL ASSAYS. HERE WE PROPOSE TO STUDY HOW THE ACTIVITY OF GRP94 IS REGULATED BY GLYCOSYLATION AND TO VISUALIZE THE CAPTURE OF A CLIENT PROTEIN. WE WILL MAKE USE OF A NOVEL IN-CELL EXPRESSION SYSTEM DEVELOPED IN OUR LAB THAT ALLOWS US TO SELECTIVELY CONTROL THE GLYCOSYLATION PATTERNS OF GRP94 AT ALL AVAILABLE SEQUONS. WE WILL EMPLOY THESE DEFINED GLYCOSYLATED SPECIES IN BOTH IN VIVO AND IN VITRO GRP94-SPECIFIC ASSAYS THAT ALLOWS FOR THE INTERROGATION OF GRP94 ACTIVITY AS A FUNCTION OF ATTACHED GLYCANS. COMBINED WITH STRUCTURAL AND BIOCHEMICAL TOOLS, WE EXPECT TO DETERMINE HOW GLYCOSYLATION REGULATES THE STRUCTURE AND FUNCTION OF GRP94 AND HOW A CLIENT PROTEIN IS CAPTURED BY THE CHAPERONE.
Obligated Amount:
388000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2023-08-08
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
DYNAMICALLY-RESOLVED STRUCTURAL STUDIES OF PROTEINS FROM FUNGAL AND BACTERIAL PATHOGENS - SUMMARY DRUG RESISTANCE AND DESENSITIZATION IS A GROWING GLOBAL CONCERN. TO OVERCOME THESE THERAPEUTIC ISSUES, DRUG DISCOVERY PIPELINES HAVE TO MAKE USE OF ALL AVAILABLE STRUCTURAL INFORMATION TO GENERATE NOVEL, POTENT AND SAFE THERAPEUTICS. CURRENT MEDICINAL CHEMISTRY EFFORTS TYPICALLY MAKE USE OF STATIC, CRYO-TEMPERATURE PROTEIN STRUCTURES, WHICH DO NOT INTEGRATE THE DYNAMICS KNOWN GOVERN PROTEIN FUNCTION. ADVANCING FROM STRUCTURE-ACTIVITY TO DYNAMIC-ACTIVITY RELATIONSHIPS WILL DIVERSIFY THE WAY WE PURSUE DRUG DISCOVERY, OPENING DOORS TO MORE ADVANCED THERAPEUTICS. TO OBTAIN THIS KNOWLEDGE, THE PROJECTS PROPOSED WILL PURSUE TIME-RESOLVED STRUCTURAL STUDIES OF MEDICALLY-RELEVANT PROTEINS FROM FUNGAL AND BACTERIAL PATHOGENS. ALTHOUGH CHALLENGING, TIME- RESOLVED STRUCTURAL BIOLOGY HAS MATURED OVER THE LAST DECADE MAKING IT AMENABLE TO A WIDER RANGE OF PROTEIN TARGETS. THIS RESEARCH WILL BREAK METHODOLOGICAL BARRIERS TO SWIFTLY OBTAIN DYNAMIC- ACTIVITY RELATIONSHIPS, FROM WHICH WE WILL DETERMINE HOW DYNAMICS CORRELATE TO PROTEIN FUNCTION. COMPLEMENTARY BIOCHEMICAL AND BIOPHYSICAL STUDIES WILL BE USED TO UNAMBIGUOUSLY RESOLVE PROTEIN METASTABLE INTERMEDIATES. METHODS SUCH AS PHOTOCAGING AND CRYO-TRAPPING ARE USED TO TRIGGER SYNCHRONIZE PROTEIN FUNCTION IN THE SAMPLE, MAKING USE OF THE WORK AND EXPERTISE OF THE PI AS WELL AS THE AVAILABLE FACILITIES, INCLUDING A DEDICATED ORGANIC SYNTHESIS LABORATORY. TWO INITIAL TARGETS WILL BE PURSUED. THE FIRST ONE, C. AURIS 3-DEOXY-D-ARABINOHEPTULOSONATE 7- PHOSPHATE SYNTHASE (DAHPS) IS AN ENZYME ESSENTIAL FOR FUNGAL SURVIVAL AS IT CATALYSIS A STEP IN THE BIOSYNTHESIS OF AROMATIC AMINO-ACIDS. IT IS CONSIDERED A PROMISING DRUG TARGET TO CURRENT ANTIFUNGALS AND IT IS DYNAMICALLY ALLOSTERICALLY REGULATED. THE SECOND TARGET IS RUBRERYTHRIN FROM B. PSEUDOMALLEI, A PROTEIN BELIEVED TO BE RESPONSIBLE FOR OXIDATIVE STRESS RESPONSES FOR WHICH THE MECHANISM IS STILL UNCLEAR. BOTH PROJECTS WILL BE TARGETED USING AN OVERARCHING METHODOLOGICAL PIPELINE WHICH WILL GENERATE NEW INSIGHTS INTO DYNAMIC-ACTIVITY RELATIONSHIPS AND PROVIDE STRUCTURES OF SHORT-LIVED INTERMEDIATES. BEYOND THE CUTTING-EDGE WORK PROPOSED IN THIS GRANT, THESE DISCOVERIES WILL FUEL A LONG-TERM RESEARCH PROGRAM FOCUSING ON HARNESSING DYNAMIC INFORMATION TO DRIVE NOVEL DRUG DESIGN. THE FUNDAMENTAL WORK PROPOSED IN THIS GRANT WILL FILL GAPS IN OUR KNOWLEDGE OF PROTEIN MECHANISM AND ITS RELATIONSHIP TO DYNAMICS, AND WILL PAVE THE WAY TO NOVEL DRUG DISCOVERY APPROACHES. THE PROPOSED TIME-RESOLVED EXPERIMENTS ARE CHALLENGING BUT MADE POSSIBLE BY THE MULTI-DISCIPLINARY EXPERTISE OF THE PI AS WELL AS STRONG COLLABORATIONS THAT DRIVE FERTILE SCIENTIFIC DISCUSSIONS AND UNOBSTRUCTED ACCESS TO CUTTING EDGE TECHNOLOGY AND FACILITIES IN THE USA AND ABROAD.
Obligated Amount:
41118.03
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2023-03-27
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
STRUCTURE MEETS FUNCTION FOR OATP1B1, A TRANSPORTER INVOLVED IN THE UPTAKE OF ENDOGENOUS AND XENOBIOTIC MATERIALS AND DRUGS - PROJECT SUMMARY THE POLYMORPHIC TRANSPORTER OATP1B1 PLAYS SIGNIFICANT ROLES IN THE HEPATIC UPTAKE AND DISPOSITION OF ENDOGENOUS MOLECULES AND DRUGS. FURTHER, OATP1B1 IS INVOLVED IN NUMEROUS DRUG-DRUG INTERACTIONS (DDIS) DUE TO ITS MULTISPECIFICITY. DESPITE DECADES OF RESEARCH, MANY FACTORS RELATED TO THE DETERMINANTS OF LIGAND BINDING, TRANSPORT MECHANISM AND ENERGETICS, AS WELL AS THE STRUCTURE OF THIS IMPORTANT TRANSPORTER ARE UNRESOLVED. THE LONG-TERM GOAL IS TO CHARACTERIZE HEPATIC TRANSPORT AT THE MICROSCOPIC AND MACROSCOPIC LEVELS. DUE TO THE FUNCTIONAL IMPORTANCE OF OATP1B1 IN LIVER CLEARANCE, THIS IS THE FIRST TARGET STUDIED. THE CENTRAL HYPOTHESIS IS THAT STRUCTURES OF HUMAN OATP1B1 AND FUNCTIONAL ASSAYS PERFORMED ON ISOLATED PROTEINS WILL UNEQUIVOCALLY DEFINE THE MECHANISM OF LIGAND BINDING, TRANSPORT, AND INHIBITION. THE RATIONALE THAT UNDERLIES THIS RESEARCH IS THAT PROTEIN STRUCTURES COUPLED WITH UNAMBIGUOUS, REPRODUCIBLE ACTIVITY ASSAYS ARE ABSOLUTELY REQUIRED TO FULLY CHARACTERIZE THE MECHANISM OF TRANSPORT AND RESOLVE LONG-STANDING CONFLICTING DATA REPORTED IN THE LITERATURE. ESTABLISHING ROBUST EXPRESSION AND PURIFICATION PROTOCOLS FOR HUMAN OATP1B1 FACILITATES PURSUING THE TWO SPECIFIC AIMS: 1) RESOLVE STRUCTURES OF OATP1B1 BY CRYO-EM AND ANALYZE THEIR MOTIONS BY MD SIMULATIONS. 2) FUNCTIONALLY CHARACTERIZE THE TRANSPORT MECHANISM OF OATP1B1. FOR THE 1ST AIM, THE OPTIMAL CONDITIONS THAT RESULT IN THE HIGHEST IMAGE QUALITY FOR CRYO-EM OF OATP1B1 WOULD BE SCREENED, AND DATA WOULD BE ACQUIRED IN THE PRESENCE AND ABSENCE OF LIGANDS. THE CRYO-EM STUDIES WILL BE AUGMENTED BY MD SIMULATIONS AND DOCKING STUDIES THAT WOULD REVEAL DETAILS THAT ARE NOT ACCESSIBLE BY MERE STRUCTURAL ANALYSIS. THE DIFFERENT BIOCHEMICAL CONDITIONS (APO AND HOLO) INCREASE THE LIKELIHOOD OF A) SOLVING THE STRUCTURAL DETERMINANTS OF THE BINDING OF VARIOUS LIGANDS (WITH DISTINCT CHEMISTRIES) TO THE TWO LIGAND-BINDING SITES OF OATP1B1. B) SOLVING THE STRUCTURES OF MULTIPLE CONFORMATIONS THAT ARE PART OF THE TRANSPORT CYCLE. FOR THE 2ND AIM, WE WILL USE PURIFIED PROTEIN RECONSTITUTED INTO PROTEOLIPOSOMES TO CHARACTERIZE THE INHERENT PROPERTIES OF OATP1B1 SUCH AS THE ENERGIZING ION FOR TRANSPORT, THE INFLUENCE OF THE MEMBRANE VOLTAGE, AND PH. THOSE RESULTS WOULD BE COMPARED WITH CELLULAR ASSAYS THAT INCLUDE INTACT CELLULAR MACHINERY, AND OTHER PLASMA MEMBRANE TRANSPORTERS THAT MIGHT DIRECTLY OR INDIRECTLY AFFECT OATP1B1. THE RESEARCH PROPOSED IN THIS APPLICATION IS INNOVATIVE, IN THE APPLICANT’S OPINION BECAUSE IT INTRODUCES TWO METHODOLOGIES THAT HAVE NEVER BEEN EXPLORED FOR ANY OATP ISOFORM. THESE COULD UNCOVER A PLETHORA OF NOVEL INSIGHTS INTO THE STRUCTURE/FUNCTION RELATIONSHIP OF OATP1B1. THE PROPOSED RESEARCH IS SIGNIFICANT SINCE OATP1B1 IS INVOLVED IN DDIS OF SEVERAL COMMONLY PRESCRIBED DRUGS, SOMETIMES RESULTING IN LIFE-THREATENING SITUATIONS. THIS STUDY WOULD UNRAVEL THE EXACT DETERMINANTS OF LIGAND BINDING TO OATP1B1 AND TRANSPORT. ULTIMATELY, THE STRUCTURAL AND FUNCTIONAL KNOWLEDGE GENERATED HERE HAS THE POTENTIAL TO AID IN THE DESIGN OF DRUGS THAT EXHIBIT A LOWER PROPENSITY FOR DDIS.
Obligated Amount:
1170360.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2022-09-16
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
NEW TECHNIQUES FOR DETECTING AND HANDLING NANOCRYSTALS FOR CUTTING EDGE STRUCTURAL BIOLOGY METHODS - PROJECT SUMMARY DETERMINING THE DETAILED STRUCTURAL CHARACTERISTICS OF BIOMOLECULES RELEVANT TO HUMAN HEALTH AND DISEASE IS ONE OF THE MOST CRUCIAL TOOLS IN OUR ARSENAL FOR UNDERSTANDING DISEASE ETIOLOGY AND MECHANISM, AND FOR BEING ABLE TO DEVELOP NEW THERAPEUTICS THAT TARGET THESE MOLECULAR ENTITIES. THERE ARE NEW TECHNIQUES IN STRUCTURAL BIOLOGY, INCLUDING SERIAL FEMTOSECOND CRYSTALLOGRAPHY, SERIAL SYNCHROTRON CRYSTALLOGRAPHY, AND MICROCRYSTAL ELECTRON DIFFRACTION, THAT HAVE THE POTENTIAL TO GREATLY ADVANCE STRUCTURE DETERMINATION OF BIOMOLECULES AND TO EMPOWER ACCESS TO STRUCTURAL DETAILS THAT HAVE DEED CHARACTERIZATION VIA OTHER STRUCTURAL METHODS. THESE NEW STRUCTURAL METHODS ALL RELY ON BEING ABLE TO GENERATE, DETECT AND APPROPRIATELY HANDLE EXTREMELY SMALL CRYSTALLINE SAMPLES OF BIOMOLECULES. THIS REQUIREMENT FOR SUB- MICRON SIZED CRYSTALS IS ONE OF THE KEY FEATURES OF THESE TECHNOLOGIES, AND PRESENTS A MAJOR OBSTACLE TO THE ADVANCEMENT OF THESE METHODS FOR STRUCTURE DETERMINATION. THIS PROPOSAL PRESENTS INNOVATIVE TECHNOLOGIES FOR BOTH IMAGE ANALYSIS AND SAMPLE HANDLING EXPRESSLY DESIGNED TO ADDRESS THE SPECIC CHALLENGES OF WORKING WITH SUBMICRON CRYSTALS. WE PLAN TO USE NONLINEAR OPTICAL MICROSCOPY METHODS COUPLED WITH PURPOSE-BUILT APPLICATION OF POINT PROCESS MODELING AND WAVELET IMAGE ANALYSIS APPROACHES TO PROVIDE COMPUTATIONAL TOOLS NEEDED TO ENABLE DETECTION AND CHARACTERIZATION OF SUBMICRON SAMPLES THAT ARE INVISIBLE TO THE BRIGHTELD MICROSCOPY TOOLS THAT ARE TYPICALLY USED IN SAMPLE GENERATION AND EXPERIMENTAL SET UP FOR CRYSTAL BASED STRUCTURAL BIOLOGY. IN ADDITION, WE WILL EXAMINE DIFFERENT XED TARGET PLATFORMS TO REDUCE SAMPLE HANDLING, MINIMIZING POTENTIAL CRYSTAL DAMAGE, AS WELL AS TEST USE OF ACOUSTIC DROPLET EJECTION TECHNIQUES FOR NANOLITER VOLUME SAMPLE TRANSFER. THESE INNOVATIONS WILL BE A POWERFUL ADDITION TO STRUCTURAL BIOLOGY TOOLBOX FOR LEVERAGING THE CUTTING EDGE DIFFRACTION BASED METHODS CURRENTLY AVAILABLE FOR STRUCTURE DETERMINATION. THESE TECHNOLOGY DEVELOPMENTS WILL BREAK THROUGH KEY BARRIERS TO THE WIDESPREAD USE OF THESE CUTTING EDGE STRUCTURAL METHODS.
Obligated Amount:
1183732.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Trademarks Section

Serial Number:
87006273
Mark:
CURE-OSITY
Status:
ABANDONED-FAILURE TO RESPOND OR LATE RESPONSE
Mark Type:
SERVICE MARK
Application Filing Date:
2016-04-19
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
CURE-OSITY
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Biomedical and Biochemical Research Services, namely, conducting research into structural biology, causes of disease, and drug discovery
International Classes:
042 - Primary Class
Class Status:
Active
Serial Number:
87006238
Mark:
CURE·OSITY
Status:
ABANDONED-FAILURE TO RESPOND OR LATE RESPONSE
Mark Type:
SERVICE MARK
Application Filing Date:
2016-04-19
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
CURE·OSITY
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Biomedical and Biochemical Research Services, namely, conducting research into structural biology, causes of disease, and drug discovery
International Classes:
042 - Primary Class
Class Status:
Active

Tax Exempt

Employer Identification Number (EIN) :
16-0807558
Classification:
Educational Organization, Scientific Organization, Local Association of Employees, Horticultural Organization, Business League, Voluntary Employees' Beneficiary Association (Govt. Emps.), Mutual Ditch or Irrigation Co., Cemetery Company, Other Mutual Corp. or Assoc.
Ruling Date:
1957-12
Deductibility:
Type of organization and use of contribution: A public charity. Deductibility Limitation: 50% (60% for cash contributions)

Paycheck Protection Program

Date Approved:
2020-05-01
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
484757
Current Approval Amount:
484757
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
489816.55

Related by officers

THE CORPORATION

ARSHIA DESIGNS INC. AAA VACUUM CORP. ATLANTICA TELECOM, INC. MISTY SPORTSWEAR, INC. FAT JAMS ELECTRONICS INC. CROQUEMBOUCHE, INC. LONG BEACH PEDIATRIC GROUP, P.C. LAW OFFICES OF JOSEPH A. GRECO, P.C. TEREZ, INC. 732 CINNAMON BEACH INC.

Related by address

73 HIGH STREET, BUFFALO, NY, United States, 14203

COLYSIS, INC. INCURON, INC. STATERA BIOPHARMA, INC. LIMITED LIABILITY COMPANY "INCURON"

Date of last update: 19 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated